180 Life Sciences - Warrants (07/11/2025) Return on Equity

180 Life Sciences - Warrants (07/11/2025) (ATNFW) currently reports a ROE of -352581.33%. That is below the Healthcare sector average of 20.77%. Use the charts on this page to explore 180 Life Sciences - Warrants (07/11/2025)'s ROE history and peer comparisons.

180 Life Sciences - Warrants (07/11/2025)'s ROE of -352581.33% is lower than the Healthcare sector average of 20.77%. That is roughly 1697955.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but 180 Life Sciences - Warrants (07/11/2025)'s current -352581.33% should be judged against Healthcare norms (sector average: 20.77%) and against ATNFW's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -352581.33%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.77%. From there, open related valuation or income-statement pages for 180 Life Sciences - Warrants (07/11/2025), and consider following ATNFW for alerts when major investors trade the stock.

180 Life Sciences - Warrants (07/11/2025) is classified in the Healthcare sector. On ROE, it currently shows -352581.33% versus a sector average near 20.77%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ATNFW with unrelated industries.